The process through which novel candidate pharmaceuticals are found in the domains of medicine, biotechnology, and pharmacology is known as drug discovery. In the past, medications were found by separating the active component from conventional treatments or by accident, such with penicillin. More recently, a procedure known as classical pharmacology was used to screen chemical libraries of synthesised small molecules, natural products, or extracts in intact cells or complete organisms to discover compounds that had a desired therapeutic effect. It has become standard practise to use high throughput screening of large compound libraries against isolated biological targets that are hypothesised to be disease-modifying in a method known as reverse pharmacology since the sequencing of the human genome enabled rapid cloning and synthesis of large quantities of purified proteins. Hits from these screenings are next evaluated for effectiveness in cells and then on animals. The identification of screening hits, medicinal chemistry, and optimization of those hits to improve their affinity, selectivity (to reduce the possibility of side effects), efficacy/potency, metabolic stability (to increase the half-life), and oral bioavailability are all essential components of modern drug discovery. Drug development can proceed after a chemical has been found that satisfies each of these criteria. Clinical studies are developed if successful.
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Exploring classical ayurvedic drugs in hypertension
Prashant Bhokardankar, Datta Meghe Ayurved College, India
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : A unique role and and impact of catalytic antibodies (abzymes) in clinical practice: A novel strategy for predicting and preventing relapse in chronic autoimmune conditions
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promise of nanotechnology in personalized & precision medicine: Drug discovery & development being partnered with nanotechnologies via the revolution at the nanoscale
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promising future of the unique translational tool to manage beta-cell population renewal and regeneration to secure the post-diabetic period
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Easily injectable, organic solvent free self assembled hydrogel platform for endoscope mediated gastrointestinal polypectomy
Hitasha Vithalani , IIT Gandhinagar, India